A cofactor‐promiscuous HMGR from the Lyme disease pathogen illuminates diversity in bacterial isoprenoid biosynthesis
Protein Science · 2026
DOI: 10.1002/pro.70766 ↗At a glance
Journal article in Protein Science, 2026. Written by Isaac A Paddy and 7 co-authors. Institution: Department of Chemical and Systems Biology, Stanford School of Medicine, Stanford, USA. Major MEDLINE topics: Borrelia burgdorferi, Bacterial Proteins, Terpenes. 75 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIH HHS, NIGMS NIH HHS, U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences.
Abstract (original language)
The Lyme disease pathogen Borrelia burgdorferi contains a highly reduced genome lacking many primary metabolic pathways. However, B. burgdorferi retains the mevalonate pathway that synthesizes isopentenyl pyrophosphate (IPP), the precursor to the peptidoglycan carrier lipid. While the mevalonate pathway and the enzyme that catalyzes its rate‐limiting step (3‐hydroxy‐3‐methyl glutaryl coenzyme A reductase, HMGR) are well studied in vertebrates, little is known about the pathway in B. burgdorferi and many pathogenic bacteria. In this work, we reveal that HMGR is a critical metabolic enzyme in B. burgdorferi . We demonstrate that loss of HMGR causes morphological defects and muted de novo synthesis of peptidoglycan; these defects are ameliorated by exogenous mevalonate and IPP. Biochemical characterization unveiled HMGR as a highly unusual cofactor‐promiscuous oxidoreductase that functions with both nicotinamide cofactors. Bioinformatics and biochemical characterization uncovered examples of similarly promiscuous HMGRs and revealed a previously unrecognized evolutionary link to cofactor choice. Moreover, structures of the enzyme reveal a highly divergent active site architecture. Together, these findings firmly establish HMGR as an opportunity target for the development of antibacterials for a diderm pathogen while highlighting cofactor promiscuity as an evolutionary acquired feature in HMGRs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Chemical and Systems Biology, Stanford School of Medicine, Stanford, USA.
- Sarafan ChEM-H Institute, Stanford University, Stanford, USA.
- Department of Biology, Stanford University, Stanford, USA.
- Howard Hughes Medical Institute, Stanford University, Stanford, USA.
- Department of Chemistry, Stanford University, Stanford, USA.
- Innovative Medicines Accelerator, Stanford University, Stanford, USA.
ORCID profiles: Isaac A Paddy, Madelyn Frazier, Laura M K Dassama
Funding
- NIH HHS
- NIGMS NIH HHS
- U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences
- Howard Hughes Medical Institute (Emerging Pathogens Initiative; Investigator)
- National Institutes of Health, National Institute of General Medical Sciences
- National Institutes of Health
Cite
APA
Paddy, I. A., McCausland, J., Frazier, M., Chatterjee, P., Setegne, M., Eidam, O., Jacobs-Wagner, C., & Dassama, L. M. K. (2026). A cofactor‐promiscuous HMGR from the Lyme disease pathogen illuminates diversity in bacterial isoprenoid biosynthesis. Protein Science. https://doi.org/10.1002/pro.70766
Vancouver
Paddy IA, McCausland J, Frazier M, Chatterjee P, Setegne M, Eidam O, et al. A cofactor‐promiscuous HMGR from the Lyme disease pathogen illuminates diversity in bacterial isoprenoid biosynthesis. Protein Science. 2026. doi:10.1002/pro.70766
BibTeX
@article{Paddy2026,
author = {Paddy, Isaac A and McCausland, Joshua and Frazier, Madelyn and Chatterjee, Poulami and Setegne, Mekedlawit and Eidam, Oliv and Jacobs-Wagner, Christine and Dassama, Laura M K},
title = {A cofactor‐promiscuous HMGR from the Lyme disease pathogen illuminates diversity in bacterial isoprenoid biosynthesis},
journal = {Protein Science},
year = {2026},
doi = {10.1002/pro.70766}
}
EUVIMED